<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565900</url>
  </required_header>
  <id_info>
    <org_study_id>V114-022</org_study_id>
    <secondary_id>2018-000066-11</secondary_id>
    <secondary_id>V114-022</secondary_id>
    <nct_id>NCT03565900</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed 1) to describe the safety, tolerability, and immunogenicity of V114
      and Prevnar 13™ in pneumococcal vaccine-naïve adult and pediatric recipients of allogeneic
      hematopoietic stem cell transplant (HSCT), and 2) to describe the safety and tolerability of
      PNEUMOVAX™23 when administered 12 months after HSCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Anticipated">November 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adult Participants: Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to 5 days after any of the Day 1, Day 30, or Day 60 vaccinations (V114 or Prevnar 13™)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness/erythema, swelling, and pain/tenderness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pediatric Participants: Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to 14 days after any of the Day 1, Day 30, or Day 60 vaccinations (V114 or Prevnar 13™)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness/erythema, swelling, pain/tenderness, and hard lump.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adult Participants: Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to 14 days after any of the Day 1, Day 30, or Day 60 vaccinations (V114 or Prevnar 13™)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pediatric Participants: Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to 14 days after any of the Day 1, Day 30, or Day 60 vaccinations (V114 or Prevnar 13™)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain/myalgia, joint pain/arthralgia, headache, tiredness/fatigue, and hives or welts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Vaccine-related Serious Adverse Event</measure>
    <time_frame>Up to the time of PNEUMOVAX™23 vaccination (12 months after HSCT and up to 9 months after Day 1)</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Immunoglobulin G (IgG)</measure>
    <time_frame>Day 1 (Baseline) and Day 90 (30 days after the Day 60 vaccinations with V114 or Prevnar 13™)</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adult Participants: Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to 5 days after the PNEUMOVAX™23 vaccination (12 months after HSCT and approximately 6 to 9 months after Day 1)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness/erythema, swelling, and pain/tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Participants: Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to 5 days after the PNEUMOVAX™23 vaccination (12 months after HSCT and approximately 6 to 9 months after Day 1)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness/erythema, swelling, pain/tenderness, and hard lump</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Participants: Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to 14 days after the PNEUMOVAX™23 vaccination (12 months after HSCT and approximately 6 to 9 months after Day 1)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Participants: Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to 14 days after the PNEUMOVAX™23 vaccination (12 months after HSCT and approximately 6 to 9 months after Day 1)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain/myalgia, joint pain/arthralgia, headache, tiredness/fatigue, and hives or welts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Vaccine-related Serious Adverse Event</measure>
    <time_frame>Up to 1 month after PNEUMOVAX™23 vaccination (12 months after HSCT and approximately 6 to 10 months after Day 1)</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Participants with GVHD: Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to 5 days after the fourth V114 or Prevnar 13™ vaccination (12 months after HSCT and approximately 6 to 9 months after Day 1)</time_frame>
    <description>This Outcome Measure applies to adult participants who develop GVHD within 12 months of HSCT and receive V114 or Prevnar 13™ as the fourth vaccination. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness/erythema, swelling, and pain/tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Participants with GVHD: Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to 14 days after the fourth V114 or Prevnar 13™ vaccination (12 months after HSCT and approximately 6 to 9 months after Day 1)</time_frame>
    <description>This Outcome Measure applies to pediatric participants who develop GVHD within 12 months of HSCT and receive V114 or Prevnar 13™ as the fourth vaccination. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness/erythema, swelling, pain/tenderness, and hard lump.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Participants with GVHD: Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to 14 days after the fourth V114 or Prevnar 13™ vaccination (12 months after HSCT and approximately 6 to 9 months after Day 1)</time_frame>
    <description>This Outcome Measure applies to adult participants who develop GVHD within 12 months of HSCT and receive V114 or Prevnar 13™ as the fourth vaccination. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Participants with GVHD: Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to 14 days after the fourth V114 or Prevnar 13™ vaccination (12 months after HSCT and approximately 6 to 9 months after Day 1)</time_frame>
    <description>This Outcome Measure applies to pediatric participants who develop GVHD within 12 months of HSCT and receive V114 or Prevnar 13™ as the fourth vaccination. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain/myalgia, joint pain/arthralgia, headache, tiredness/fatigue, and hives or welts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with GVHD: Percentage of Participants with a Vaccine-related Serious Adverse Event</measure>
    <time_frame>Up to 6 months after the fourth V114 or Prevnar 13™ vaccination (12 months after HSCT and approximately 6 to 15 months after Day 1)</time_frame>
    <description>This Outcome Measure applies to participants who develop GVHD within 12 months of HSCT and receive V114 or Prevnar 13™ as the fourth vaccination. An SAE is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity</measure>
    <time_frame>Day 1 (Baseline) and Day 90 (30 days after the Day 60 vaccinations with V114 or Prevnar 13™)</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Day 90 (30 days after the Day 60 vaccinations with V114 or Prevnar 13™)</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Day 90 (30 days after the Day 60 vaccinations with V114 or Prevnar 13™)</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic graft-versus-host-disease (GVHD) during the first year after HSCT will receive V114 instead of PNEUMOVAX™23 as their fourth dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic GVHD during the first year after HSCT will receive Prevnar 13™ instead of PNEUMOVAX™23 as their fourth dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PNEUMOVAX™23</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received a human leukocyte antigen (HLA) compatible donor including haploidentical and
             mismatched (related or unrelated) first allogeneic HSCT (i.e., bone marrow or
             peripheral blood stem cell) 90 to 180 days prior to randomization.

          -  Received the allogeneic HSCT for acute lymphoblastic leukemia (ALL) in first or second
             remission, acute myeloid leukemia (AML) in first or second remission, chronic myeloid
             leukemia (CML) in first chronic or accelerated phase, Hodgkin's lymphoma,
             non-Hodgkin's lymphoma, myelodysplastic syndrome (MDS), myelofibrosis and
             myeloproliferative diseases, and non-malignant disease such as aplastic anemia or
             sickle cell disease in participants ≥18 years of age and any non-malignant disease for
             participants 3 to &lt;18 years of age.

          -  Life expectancy &gt;12 months after allogeneic HSCT, according to investigator judgement.

          -  Clinically stable engraftment according to investigator judgment.

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding, and at least 1 of the following conditions applies: a) not a woman of
             childbearing potential (WOCBP) OR b) a WOCBP who agrees to use acceptable
             contraceptive methods during the treatment period and for at least 6 weeks after the
             last dose of study intervention.

        Exclusion Criteria:

          -  Receipt of a previous allogeneic HSCT.

          -  Received allogeneic HSCT with ex-vivo graft manipulation, in vivo T cell depletion
             with alemtuzumab, or haploidentical allogeneic HSCT with high dose anti-thymocyte
             globulin.

          -  Received allogeneic HSCT for multiple myeloma or, for participants ≥18 years of age
             only, for any nonmalignant diseases except sickle cell disease and aplastic anemia.

          -  Persistent or relapsed primary disease after allogeneic HSCT.

          -  History of severe GVHD (Grade 3 or 4 GVHD) after allogeneic HSCT.

          -  Planned organ transplantation after allogeneic HSCT.

          -  History of culture-positive pneumococcal disease occurring after allogeneic HSCT.

          -  Known hypersensitivity to any component of pneumococcal polysaccharide vaccine,
             pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.

          -  History of acquired immunodeficiency such as documented HIV infection, or anatomic
             asplenia.

          -  Coagulation disorder contraindicating intramuscular vaccinations.

          -  Severe hepatic impairment (defined as Child-Pugh Class C) at Screening.

          -  Serum aspartate transaminase (AST) or alanine transaminase (ALT) &gt;5 × upper limit of
             normal (ULN) or serum total bilirubin &gt;2.5 × ULN at Screening.

          -  A WOCBP who has a positive urine or serum pregnancy test before the 1st vaccination.

          -  Received chimeric antigen receptor T-cell (CAR-T) therapy or checkpoint inhibitor
             directed therapy (i.e., anti-Programmed Cell Death (PD)-1) after allogeneic HSCT.

          -  Received or planned to receive anti-Cluster of Differentiation (CD) 20 B-cell targeted
             therapy (e.g., rituximab) after allogeneic HSCT.

          -  Non-study pneumococcal vaccine administered after allogeneic HSCT, or is expected to
             receive non-study pneumococcal vaccine during participation in the study.

          -  Is currently participating or has participated in an interventional clinical study
             with an investigational compound/agent or device within 2 weeks of participating in
             this current study, or plans to receive any investigational compound/agent or device
             (in addition to existing therapy) within 2 weeks of any vaccination, that in the
             opinion of the investigator would interfere with the evaluation of the study
             objectives.

          -  Is, at the time of signing informed consent, a user of recreational or illicit drugs
             or has had a recent history (within the last year) of drug or alcohol abuse or
             dependence as assessed by the study investigator.

          -  Has history or current evidence of any condition, therapy, laboratory test result
             abnormality, or other circumstance that might expose the participant to risk by
             participating in the study, confound the results of the study, or interfere with the
             participant's participation for the full duration of the study.

          -  Is or has an immediate family member who is investigational site or Sponsor staff
             directly involved with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Health Care ( Site 0005)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado ( Site 0166)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-777-5179</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida ( Site 0011)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>352-265-0111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago ( Site 0016)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-834-4430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation ( Site 0001)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center ( Site 0007)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>913-588-3894</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins - University ( Site 0023)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-614-6702</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital ( Site 0167)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-302-6808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center ( Site 0164)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>718-741-2342</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center ( Site 0010)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-803-7468</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation ( Site 0168)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-445-0453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University ( Site 0018)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Texas Children's Hospital ( Site 0165)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>832-824-1580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital ( Site 0041)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children s Hospital at Westmead ( Site 0191)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital ( Site 0040)</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Health-Austin Hospital ( Site 0038)</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital ( Site 0037)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61390762296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital ( Site 0039)</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc ( Site 0122)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3227641800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven ( Site 0119)</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge-Oostende ( Site 0118)</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Delta ( Site 0120)</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3251237322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liege ( Site 0121)</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3243667201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Rafael ( Site 0049)</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+557132816965</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Belo Horizonte ( Site 0050)</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+553132388849</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Cancer e Transplante de Curitiba ICTR ( Site 0051)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80510-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>javascriptvoid0</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority QEII-HSC ( Site 0033)</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre ( Site 0032)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>905527210043251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0031)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>51425234003295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe ( Site 0077)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+57314890560300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0073)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5723319090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco de Cali S.A ( Site 0075)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5725186000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice ( Site 0084)</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz Besancon ( Site 0085)</name>
      <address>
        <city>Besancon</city>
        <state>Doubs</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble Hopital Nord ( Site 0083)</name>
      <address>
        <city>La Tronche</city>
        <state>Isere</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33472117405</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez ( Site 0090)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor ( Site 0081)</name>
      <address>
        <city>Creteil</city>
        <state>Val-de-Marne</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine ( Site 0089)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33149282624</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf ( Site 0107)</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln ( Site 0105)</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49022147897340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Mainz ( Site 0106)</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez ( Site 0187)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5283486136</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicio de hematologia Universidad Autonoma de Nuevo Leon ( Site 0057)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+528186756718</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 0062)</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525510840900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0058)</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez ( Site 0061)</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525561521239</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Espanol ( Site 0059)</name>
      <address>
        <city>Mexico</city>
        <zip>11520</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525552547093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia. ( Site 0060)</name>
      <address>
        <city>Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset ( Site 0143)</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Lan [se-01]</state>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46858582507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset ( Site 0144)</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala Lan [se-03]</state>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset ( Site 0145)</name>
      <address>
        <city>Goteborg</city>
        <state>Vastra Gotalands Lan [se-14]</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46313427358</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

